

Erratum

A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial

Giovanni Abbruzzese^a, Jaime Kulisevsky^b, Bruno Bergmans^c, Juan C. Gomez-Esteban^d, Georg Kägi^e, Jason Raw^f, Alessandro Stefani^g, Tobias Warnecke^h, Wolfgang H. Jostⁱ and the SYNAPSES Study Investigators Group

^a*DINOGMI, University of Genoa, Genova, Italy*

^b*Sant Pau Hospital, Universitat Autònoma de Barcelona, CIBERNED, Barcelona, Spain*

^c*Department of Neurology, AZ St-Jan Brugge-Oostende AV, Campus Brugge, Brugge & Ghent University Hospital, Ghent, Belgium*

^d*Biocruces Research Institute, Barakaldo, Spain*

^e*Department of Neurology, Cantonal Hospital St.Gallen, Switzerland*

^f*Fairfield General Hospital, Bury, Greater Manchester, UK*

^g*Parkinson Center, University Policlinico Tor Vergata, Roma, Italy*

^h*Department of Neurology, University of Muenster, Muenster, Germany*

ⁱ*Parkinson-Klinik Ortenau, University of Freiburg, Wolfach, Germany*

Pre-press 10 July 2021

[*Journal of Parkinson's Disease*, **11** (1) (2021), 187–198, DOI 10.3233/JPD-202224]

<https://content.iospress.com/articles/journal-of-parkinsons-disease/jpd202224>

On page 197, in chapter “Synapses study Investigators group”, under “Italy”, the name of “Passarella B” should be added.